Anthropic Nears $15 Billion Credit Deal Ahead of IPO 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
Xiaomi Shares Jump on Europe EV Expansion Plan 
Qantas Near-Miss Raises Sydney Air Traffic Controller Fatigue Concerns 
Lynas Rare Earths Shares Rise After Takeover Talks Revealed 
South Korea, US Discuss Chip Investments Amid Tariff Plans 
Deutsche Telekom Shares Rise as Elliott Pushes Against T-Mobile Merger 
ByteDance Secures $29.6 Billion Loan to Boost AI Investment 
Berkshire Hathaway Eyes Bigger Stakes in Japan’s Top Trading Houses 
Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability 
Microsoft to Reveal Azure Revenue in Major Reporting Shake-Up 
Audi, SAIC Launch China Innovation Hub for New AUDI Models 
OpenAI Nears Astra AI Model Launch With Safety Focus 
Tesla Cybercab Launch Puts Robotaxi Ambitions in Focus 
Volkswagen Approves 50,000 More Job Cuts in Major Restructuring 
Add as a preferred source on Google
AUSTIN, Texas, Feb. 23, 2018 -- Vermillion, Inc. (Nasdaq:VRML), a bio-analytical solutions company focused on gynecologic disease, announced today that Valerie Palmieri, President and Chief Executive Officer, and Robert Beechey, Chief Financial Officer, are scheduled to participate in BTIG’s 2018 Healthcare Conference from February 28, 2018 through March 1, 2018 in Snowbird, Utah. BTIG’s annual conference will bring together more than 100 leading healthcare companies with institutional investor clients.
About BTIG
BTIG is a global financial services firm specializing in institutional trading, investment banking, research and related brokerage services. With an extensive global footprint and more than 550 employees, BTIG, LLC and its affiliates operate out of 17 cities throughout the U.S., and in Europe, Asia and Australia. BTIG offers execution, expertise and insights for equities, equity derivatives, ETFs and fixed income, currency and commodities (futures, commodities, foreign exchange, interest rates, credit, and convertible and preferred securities). The firm’s core capabilities include global execution, portfolio, electronic and outsource trading, transition management, investment banking, prime brokerage, capital introduction, corporate access, research and strategy, commission management and more.
About Vermillion
Vermillion, Inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic and bio-analytical solutions that help physicians diagnose, treat and improve gynecologic health outcomes for women. Vermillion, along with its prestigious scientific collaborators, discovers, develops, and delivers innovative diagnostic and technology tools that help women with serious diseases. The company's initial in vitro diagnostic test, OVA1® (MIA), was the first FDA-cleared, protein-based In Vitro Diagnostic Multivariate Index Assay, and represented a new class of software-based liquid biopsy in vitro diagnostics. In March 2016, Vermillion received FDA clearance for Overa™, a Multivariate Index Assay 2nd Generation (MIA2G) test with significantly improved specificity and ease of use. For additional information, including published clinical trials, visit www.vermillion.com.
Investor Relations Contact:
Jeremy Feffer
LifeSci Advisors LLC
Tel 212-915-2568
[email protected]
